http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130702:nBw025564a
   Purchase Orders to Result in Sales of up to $3 Million in LuViva Devices andDisposablesNORCROSS, Ga. & ANKARA, Turkey--(Business Wire)--Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) and its Turkishdistributor, I.T.E.M. Medical Technologies Group, today announced a majorprogram for early detection and prevention of cervical cancer involving GuidedTherapeutics` LuViva Advanced Cervical Scan. The program for 2013 and 2104, tobe funded by Turkey`s Ministry of Health, would involve the order and placementof up to $3 million worth of LuViva Advanced Cervical Scan devices andassociated disposables. In addition, the Ministry of Health will conductclinical trials to assess the utility of LuViva within a broader nationalprogram of cervical cancer control. "The selection of the LuViva Advanced Cervical Scan for inclusion in Turkey`scervical cancer prevention program is an honor which speaks to the clinicaladvantages of our technology, including safety, diagnostic accuracy and economicefficiency," said Mark L. Faupel, Ph.D., CEO and President of GuidedTherapeutics, Inc. "We look forward to working with I.T.E.M. and the Ministry toimprove health care for all Turkish women." Zafer Yazici, CEO and President of I.T.E.M. Medical Technologies Group, added,"We are pleased to be in a partnership with the Ministry of Health and GuidedTherapeutics to bring LuViva into clinical practice for cervical cancerprevention. The program is consistent with our commitment to bring advancedmedical technologies to this region of the world. We expect that LuViva'sinnovative technology will establish Turkey as a leader in cancer controlstrategies, while raising the bar in women's healthcare." Under terms of the program, initial shipments are expected to begin this quarterand last through the end of 2014. Each year in Turkey, about two million women undergo Pap test screening forcervical cancer, with as many as 200,000 receiving an abnormal Pap result.Recently, human papillomavirus (HPV) screening for women was introduced as analternative to Pap testing. Women who demonstrate either an abnormal Pap orPositive HPV test are then scheduled for a follow-up exam, called a colposcopy,which typically includes a painful biopsy of cervical tissue. LuViva is designedto be used before colposcopy to identify women without disease and prevent themfrom receiving unnecessary biopsies. Besides the obvious reduction in patientdiscomfort, there is also expected to be a reduction in healthcare costs. All ofthis is accomplished utilizing a painless test that takes about one minute andproduces a result immediately at the point of care. About LuViva Advanced Cervical ScanLuViva is a technologically advanced diagnostic device that scans the cervixwith light and uses spectroscopy to measure how light interacts with thecervical tissue. Spectroscopy identifies chemical and structural indicators ofprecancer that may be below the surface of the cervix or misdiagnosed as benign.This technique is called biophotonics. Unlike Pap, HPV tests or biopsies, LuVivadoes not require laboratory analysis or a tissue sample, and is designed toprovide results immediately, which eliminates costly, painful and unnecessarytesting. LuViva is designed for use with women who have undergone initialscreening and are called back for follow up with a colposcopy examination, whichin many cases involves taking a biopsy of the cervix. The device is used inconjunction with the LuViva Cervical Guide single-use, patient interface andcalibration disposable. The LuViva Advanced Cervical Scan is compliant with both Edition 2 and Edition 3CE standards, has marketing approval from Health Canada and the Singapore HealthSciences Authority, and is under U.S. Food and Drug Administration Premarketreview. About I.T.E.M. Medical Technologies GroupI.T.E.M Innovations Group is a leading medical technology consortium in Turkey.The companies within the I.T.E.M. Group include ROTA ILERI CO. LTD. and NOVATEKCO. LTD., which were established in 1990 and have successfully introduced animpressive number of innovative medical technologies to the market. I.T.E.MInnovations Group has been one of the most dynamic, fast growing and trustworthymedical companies in the region for more than 20 years. About Guided TherapeuticsGuided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) is developing a rapid andpainless testing platform for the early detection of disease based on itspatented biophotonic technology that utilizes light to detect disease at thecellular level. The Company`s first product is the LuViva Advanced CervicalScan, a non-invasive device used to detect cervical disease instantly and at thepoint of care. In a multi-center clinical trial, with women at risk for cervicaldisease, the technology was able to detect cervical cancer up to two yearsearlier than conventional modalities, according to published reports. GuidedTherapeutics is also developing a non-invasive test for the early detection ofesophageal cancer using the technology platform. For more information, visit:
  www.guidedinc.com.
  The Guided Therapeutics LuViva Advanced Cervical Scan is an investigationaldevice and is limited by federal law to investigational use. LuViva, the wavelogo and "Early detection, better outcomes" are registered trademarks owned byGuided Therapeutics, Inc.Forward-Looking Statements Disclaimer: A number of the matters and subject areasdiscussed in this news release that are not historical or current facts dealwith potential future circumstances and developments. The discussion of suchmatters and subject areas is qualified by the inherent risks and uncertaintiessurrounding future expectations generally and also may materially differ fromGuided Therapeutics` actual future experience involving any of or more of suchmatters and subject areas. Such risks and uncertainties include those related tothe early stage of products in development, the uncertainty of market acceptanceof products, the uncertainty of development or effectiveness of distributionchannels, the intense competition in the medical device industry, theuncertainty of capital to develop products, the uncertainty of regulatoryapproval of products, dependence on licensed intellectual property, as well asthose that are more fully described from time to time under the heading "RiskFactors" in Guided Therapeutics` reports filed with the SEC, including GuidedTherapeutics` Annual Report on Form 10-K for the fiscal year ended December 31,2012, and subsequent quarterly reports.  Cameron AssociatesInvestor Relations:Alison Ziegler, 212-554-5469orGuided Therapeutics, Inc.Bill Wells, 770-242-8723, ext. 241 Copyright Business Wire 2013